DQ 65-79, A Peptide Derived from HLA Class II, Mimics p21 to Block T Cell Proliferation

Journal of Immunology

Volumn 171, Issue 10, 2003, Pages 5064-5070

  Dong, Chen ^a   Lyu, Shu Chen ^a   Krensky, Alan M ^a   Clayberger, Carol ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; HLA ANTIGEN CLASS 2; HLA DQ A03011 ANTIGEN; HLA DQ ANTIGEN; HLA DQ ANTIGEN [65-79]; LIGAND; PEPTIDE DERIVATIVE; PROTEIN P21; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; BINDING COMPETITION; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CELL GROWTH; GROWTH INHIBITION; IMMUNOPRECIPITATION; LYMPHOCYTE PROLIFERATION; MOLECULE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN INTERACTION; T LYMPHOCYTE; TWO HYBRID SYSTEM;

EID: 0242580044     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.171.10.5064     Document Type: Article

References (56)

1. Nisco, S., P. Vriens, G. Hoyt, S. C. Lyu, F. Farfan, P. Pouletty, A. M. Krensky, and C. Clayberger. 1994. Induction of allograft tolerance in rats by an HLA class-I-derived peptide and cyclosporine A. J. Immunol. 152:3786.
2. Madsen, J. C., R. A. Superina, K. J. Wood, and P. J. Morris. 1988. Immunological unresponsiveness induced by recipient cells transfected with donor MHC genes. Nature 332:161.
3. Bell, Y., D. Shoskes, P. Morris, and K. Wood. 1993. Induction of specific unresponsiveness using transfected cells expressing donor major histocompatibility complex molecules: evidence for indirect presentation of allopeptides in vivo. Transplant. Proc. 25:359.
4. Geissler, E. K., J. Wang, J. H. Fechner, Jr., W. J. Burlingham, and S. J. Knechtle. 1994. Immunity to MHC class I antigen after direct DNA transfer into skeletal muscle. J. Immunol. 152:413.
5. Murphy, B., and A. M. Krensky. 1999. HLA-derived peptides as novel immunomodulatory therapeutics. J. Am. Soc. Nephrol. 10:1346.
6. Clayberger, C., P. Parham, J. Rothbard, D. S. Ludwig, G. K. Schoolnik, and A. M. Krensky. 1987. HLA-A2 peptides can regulate cytolysis by human allogeneic T lymphocytes. Nature 330:763.
7. Clayberger, C., S. C. Lyu, P. Pouletty, and A. M. Krensky. 1993. Peptides corresponding to T-cell receptor-HLA contact regions inhibit class I-restricted immune responses. Transplant. Proc. 25:477.
8. Parham, P., C. Clayberger, S. L. Zorn, D. S. Ludwig, G. K. Schoolnik, and A. M. Krensky. 1987. Inhibition of alloreactive cytotoxic T lymphocytes by peptides from the α2 domain of HLA-A2. Nature 325:625.
9. Boytim, M. L., S. C. Lyu, R. Jung, A. M. Krensky, and C. Clayberger. 1998. Inhibition of cell cycle progression by a synthetic peptide corresponding to residues 65-79 of an HLA class II sequence: functional similarities but mechanistic differences with the immunosuppressive drug rapamycin. J. Immunol. 160:2215.
10. Ling, X., S. Kamangar, M. L. Boytim, Z. Kelman, P. Huie, S. C. Lyu, R. K. Sibley, J. Hurwitz, C. Clayberger, and A. M. Krensky. 2000. Proliferating cell nuclear antigen as the cell cycle sensor for an HLA-derived peptide blocking T cell proliferation. J. Immunol. 164:6188.
11. Murphy, B., E. Akalin, B. Watschinger, C. B. Carpenter, and M. H. Sayegh. 1995. Inhibition of the alloimmune response with synthetic nonpolymorphic class II MHC peptides. Transplant. Proc. 27:409.
12. Murphy, B., C. C. Magee, S. I. Alexander, A. M. Waaga, H. W. Snoeck, J. P. Vella, C. B. Carpenter, and M. H. Sayegh. 1999. Inhibition of allorecognition by a human class II MHC-derived peptide through the induction of apoptosis. J. Clin. Invest. 103:859.
13. Kelman, Z. 1997. PCNA: structure, functions and interactions. Oncogene 14:629.
14. Tsurimoto, T. 1999. PCNA binding proteins. Front. Biosci. 4:849.
15. Xiong, Y., G. J. Hannon, H. Zhang, D. Casso, R. Kobayahsi, and D. Beach. 1993. p21 is a universal inhibitor of cyclin kinases. Nature 366:701.
16. Flores-Rozas, H., Z. Kelman, F. B. Dean, Z. Q. Pan, J. W. Harper, S. J. Elledge, M. O'Donnell, and J. Hurwitz. 1994. Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase δ holoenzyme. Proc. Natl. Acad. Sci. USA 91:8655.
17. Waga, S., G. J. Hannon, D. Beach, and B. Stillman. 1994. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369:574.
18. Matsuoka, S., M. Yamaguchi, and A. Matsukage. 1994. D-type cyclin-binding regions of proliferating cell nuclear antigen. J. Biol. Chem. 269:11030.
19. Smith, M. L., I. T. Chen, Q. Zhan, I. Bae, C. Y. Chen, T. M. Gilmer, M. B. Kastan, P. M. O'Connor, and A. J. Fornace, Jr. 1994. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 266:1376.
20. Vairapandi, M., N. Azam, A. G. Balliet, B. Hoffman, and D. A. Liebermann. 2000. Characterization of MyD118, Gadd45, and proliferating cell nuclear antigen (PCNA) interacting domains: PCNA impedes MyD118 and Gadd45-mediated negative growth control. J. Biol. Chem. 275:16810.
21. Morgan, D. O. 1997. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu. Rev. Cell. Dev. Biol. 13:261.
22. 1 cyclin-dependent kinases. Cell 75:805.
23. Zhang, H., Y. Xiong, and D. Beach. 1993. Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes. Mol. Biol. Cell 4:897.
24. Gu, Y., C. W. Turck, and D. O. Morgan. 1993. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 366:707.
25. Gulbis, J. M., Kelman, Z., Hurwitz, J., M. O'Donnell, and J. Kuriyan. 1996. Structure of the C-terminal region of p21(WAF1/CIP1) complexed with human PCNA. Cell 87:297.
26. Chen, J., P. Saha, S. Kombluth, B. D. Dynlacht, and A. Dutta. 1996. Cyclin-binding motifs are essential for the function of p21CIP1. Mol. Cell. Biol. 16:4673.
27. Adams P. D., W. R. Sellers, S. K. Sharma, A. D. Wu, C. M. Nalin, and W. G. Kaelin, Jr. 1996. Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors. Mol. Cell. Biol. 16:6623.
28. Ball, K. L., S. Lain, R. Fahraeus, C. Smythe, and D. P. Lane. 1997. Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1. Curr. Biol. 7:71.
29. +. Proc. Natl. Acad. Sci. USA 79:2365.
30. Chen, J., R. Peters, P. Saha, P. Lee., A. Theodoras, M. Pagano, G. J. Wagner, and A. Dutta. 1996. A 39 amino acid fragment of the cell cycle regulator p21 is sufficient to bind PCNA and partially inhibit DNA replication in vivo. Nucleic Acid Res. 24:1727.
31. Pan, Z. Q., J. T. Reardon, L. Li, H. Flores-Rozas, R. Legerski, A. Sancar, and J. Hurwitz. 1995. Inhibition of nucleotide excision repair by the cyclin-dependent kinase inhibitor p21. J. Biol. Chem. 270:22008.
32. Goubin, F., and B. Ducommun. 1995. Identification of binding domains on the p21Cip1 cyclin-dependent kinase inhibitor. Oncogene 10:2281.
33. Nakanishi, M., R. S. Robetorye, O. M. Periera-Smith, and J. R. Smith. 1995. The C-terminal region of p21SDI1/WAF1/CIP1 is involved in proliferating cell nuclear antigen binding but does not appear to be required for growth inhibition. J. Biol. Chem. 21:17060.
34. Warbrick, E., D. P. Lane, D. M. Glover, and L. S. Cox. 1995. A small peptide inhibitor of DNA replication defines the site of interaction between the cyclin-dependent kinase inhibitor p21WAF1 and proliferating cell nuclear antigen. Curr. Biol. 5:275.
35. Jiang, Y., D. Chen, S. C. Lyu, X. Ling, A. M. Krensky, and C. Clayberger. 2002. DQ 65-79, a peptide derived from HLA class II, induces IκB expression. J. Immunol. 168:3323.
36. Boytim, M. L., P. Lilly, K. Drouvalakis, S. C. Lyu, R. Jung, A. M. Krensky, and C. Clayberger. 2000. A human class II MHC-derived peptide antagonizes phosphatidylinositol 3-kinase to block IL-2 signaling. J. Clin. Invest. 105:1447.
37. Dotto, G. P. 2000. p21(WAF1/Cip): more than a break to the cell cycle? Biochim. Biophys. Acta 1471:43.
38. Cooper, M. P., A. S. Balajee, and V. A. Bohr. 1999. The C-terminal domain of p21 inhibits nucleotide excision repair in vitro and in vivo. Mol. Biol. Cell 10:2119.
39. Zheleva, D. I., N. Z. Zhelev, P. M. Fischer, S. V. Duff, E. Warbrick, D. G. Blake, and D. P. Lane. 2000. A quantitative study of the in vitro binding of the C-terminal domain of p21 to PCNA: affinity, stoichiometry, and thermodynamics. Biochemistry 39:7388.
40. Tsurimoto, T. 1998. PCNA, a multifunctional ring on DNA. Biochim. Biophys. Acta 1443 23.
41. Kelman, Z., and J. Hurwitz. 1998. Protein-PCNA interactions: a DNA-scanning mechanism? Trends Biochem. Sci. 23:236.
42. Morris, G. F., and M. B. Mathews. 1989. Regulation of proliferating cell nuclear antigen during the cell cycle. J. Biol. Chem. 264:13856.
43. Nomura, A. 1994. Nuclear distribution of proliferating cell nuclear antigen (PCNA) in fertilized eggs of the starfish Asterina pectinifera. J. Cell. Sci. 107:3291.
44. Kawamura, K., Y. Kobayashi, T. Tanaka, R. Ikeda, K. Fujikawa-Yamamoto, and K. Suzuki. 2000. Intranuclear localization of proliferating cell nuclear antigen during the cell cycle in renal cell carcinoma. Anal. Quant. Cytol. Histol. 22:107.
45. Koundrioukoff, S., Z. O. Jonsson, S. Hasan, R. N. de Jong, P. C. van der Vliet, M. O. Hottiger, and U. Hubscher. 2000. A direct interaction between proliferating cell nuclear antigen (PCNA) and Cdk2 targets PCNA-interacting proteins for phosphorylation. J. Biol. Chem. 275:22882.
46. el-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817.
47. Noda, A., Y. Ning, S. F. Venable, O. M. Pereira-Smith, and J. R. Smith. 1994. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell. Res. 211:90.
48. Scott, M. T., N. Morrice, and K. L. Ball. 2000. Reversible phosphorylation at the C-terminal regulatory domain of p21(Waf1/Cip1) modulates proliferating cell nuclear antigen binding. J. Biol. Chem. 275:11529.
49. Watanabe, H., Z. Q. Pan, N. Schreiber-Agus, R. A. DePinho, J. Hurwitz, and Y. Xiong. 1998. Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57KIP2 requires binding to proliferating cell nuclear antigen. Proc. Natl. Acad. Sci. USA 95:1392.
50. Chen, J., P. K. Jackson, M. W. Kirschner, and A. Dutta. 1995. Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature 374:386.
51. Bonfanti, M., S. Taverna, M. Salmona, M. D'Incalci, and M. Broggini. 1997. p21WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth. Cancer Res. 57:1442.
52. Mutoh, M., F. D. Lung, Y. Q. Long, P. P. Roller, R. S. Sikorski, and P. M. O'Connor. 1999. A p21(Waf1/Cip1) carboxyl-terminal peptide exhibited cyclin-dependent kinase-inhibitory activity and cytotoxicity when introduced into human cells. Cancer Res. 59:3480.
53. 2 cell cycle arrest in p53-deficient cells. Oncogene 16:311.
54. Podust, V. N., L. M. Podust, F. Goubin, B. Ducommun, and U. Hubscher. 1995. Mechanism of inhibition of proliferating cell nuclear antigen-dependent DNA synthesis by the cyclin-dependent kinase inhibitor p21. Biochemistry 34:8869.
55. Warbrick, E., D. P. Lane, D. M. Glover, and L. S. Cox. 1997. Homologous regions of Fen1 and p21Cip1 compete for binding to the same site on PCNA: a potential mechanism to co-ordinate DNA replication and repair. Oncogene 14:2313.
56. Chuang, L. S., H. I. Ian, T. W. Koh, H. H. Nam, G. Xu, and B. F. Li. 1997. Human DNA-(cytosine-5) methyltransferase-PCNA complex as a target for p21WAF1. Science 277:1996.